Get the Stockscreener App
13.66
0.96%
0.13
Pre-market:
13.85
0.19
+1.39%
Amylyx Pharmaceuticals Inc stock is traded at $13.66, with a volume of 2.12M.
It is up +0.96% in the last 24 hours and down -7.14% over the past month.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.
See More
Previous Close:
$13.53
Open:
$13.38
24h Volume:
2.12M
Relative Volume:
1.53
Market Cap:
$1.51B
Revenue:
$-665.00K
Net Income/Loss:
$-144.74M
P/E Ratio:
-8.7976
EPS:
-1.5527
Net Cash Flow:
$-123.48M
1W Performance:
-4.41%
1M Performance:
-7.14%
6M Performance:
-1.59%
1Y Performance:
+261.38%
1-Day Range:
$13.20
$13.70
1-Week Range:
$13.20
$14.44
52-Week Range:
$3.11
$17.49
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
Name
Amylyx Pharmaceuticals Inc
Sector
Phone
617-682-0917
Address
55 CAMBRIDGE PARKWAY, CAMBRIDGE
Compare AMLX vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMLX
Amylyx Pharmaceuticals Inc
|
13.66 | 1.51B | -665.00K | -144.74M | -123.48M | -1.5527 |
TAK
Takeda Pharmaceutical Co Adr
|
18.04 | 56.99B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
115.93 | 48.94B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.70 | 43.30B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.14 | 33.94B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
531.82 | 23.31B | 3.18B | 1.33B | 1.04B | 27.90 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-03-26 | Initiated | Stifel | Buy |
| Jul-10-25 | Resumed | Goldman | Buy |
| Jun-24-25 | Initiated | Guggenheim | Buy |
| Jun-17-25 | Initiated | Citigroup | Buy |
| May-30-25 | Initiated | TD Cowen | Buy |
| Apr-07-25 | Upgrade | Mizuho | Neutral → Outperform |
| Nov-18-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-23-24 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-18-24 | Downgrade | Mizuho | Buy → Neutral |
| Mar-11-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-11-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Mar-08-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-08-24 | Downgrade | Goldman | Buy → Neutral |
| Jan-03-24 | Initiated | Robert W. Baird | Outperform |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Jul-24-23 | Upgrade | Goldman | Neutral → Buy |
| Mar-31-23 | Initiated | Mizuho | Buy |
| Jan-05-23 | Initiated | BofA Securities | Buy |
| May-25-22 | Initiated | Citigroup | Buy |
| Apr-01-22 | Downgrade | Goldman | Buy → Neutral |
View All
Amylyx Pharmaceuticals Inc Stock (AMLX) Latest News
Amylyx Pharmaceuticals Advances Novel Therapies for Rare Diseases: Avexitide, AMX0035, and AMX0114 Show Promise in Clinical Trials for PBH, Wolfram Syndrome, and ALS - Minichart
Amylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia - BioSpace
Amylyx Highlights Pipeline Progress in Updated Corporate Presentation - TipRanks
Amylyx Pharmaceuticals completes enrollment in Phase 3 LUCIDITY trial for PBH - Traders Union
Amylyx updates presentation: LUCIDITY and LUMINA enrollment complete; LUCIDITY topline due Q3 2026 - TradingView
Amylyx (NASDAQ: AMLX) details avexitide Phase 3 timing and cash runway into 2028 - Stock Titan
Amylyx Pharmaceuticals Q4 2025 earnings preview - MSN
Amyotrophic Lateral Sclerosis Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK, Biogen, Ionis Pharmaceuticals - Barchart.com
Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock Price Expected to Rise, Guggenheim Analyst Says - MarketBeat
Amylyx Pharmaceuticals Inc (AMLX) Shares Gap Down to $13.78 on M - GuruFocus
Maven Securities LTD Makes New $951,000 Investment in Amylyx Pharmaceuticals, Inc. $AMLX - MarketBeat
Fund Flows: Is Amylyx Pharmaceuticals Inc stock a smart retirement pickPortfolio Gains Report & Weekly Sector Rotation Insights - baoquankhu1.vn
Amylyx shares slip despite Q4 beat as investors focus on trial timeline - MSN
Amylyx Pharmaceuticals expands team to address urgent healthcare challenges - Traders Union
How Investors May Respond To Amylyx Pharmaceuticals (AMLX) Narrowed 2025 Losses And Expanded Shelf Capacity - simplywall.st
Buy Rating on Amylyx Pharmaceuticals Driven by Avexitide’s Commercial Potential and De-Risked Phase III PBH Program - TipRanks
First Light Asset Management LLC Purchases Shares of 3,355,882 Amylyx Pharmaceuticals, Inc. $AMLX - MarketBeat
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Amylyx Pharmaceuticals, Inc. $AMLX Shares Sold by Boxer Capital Management LLC - MarketBeat
Commodore Capital Boosts Stake in Amylyx Pharmaceuticals - National Today
Commodore Capital LP Purchases Shares of 4,075,478 Amylyx Pharmaceuticals, Inc. $AMLX - MarketBeat
Braidwell LP Acquires Shares of 612,841 Amylyx Pharmaceuticals, Inc. $AMLX - MarketBeat
437,391 Shares in Amylyx Pharmaceuticals, Inc. $AMLX Purchased by Ally Bridge Group NY LLC - MarketBeat
Amylyx Pharmaceuticals Inc (AMLX) Shares Down 3.06% on Mar 13 - GuruFocus
Amylyx anticipates LUCIDITY trial results in Q3 2026 while advancing PBH market strategy - MSN
Amylyx Pharmaceuticals (NASDAQ:AMLX) Shares Gap DownHere's What Happened - MarketBeat
Amylyx Pharmaceuticals Highlights Avexitide LUCIDITY Phase 3 Enrollment, Q3 Data Timing at Leerink Conf. - Yahoo Finance
Amylyx Pharmaceuticals Maps High-Stakes Path to 2027 - TipRanks
[Form 4] Amylyx Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Amylyx (NASDAQ: AMLX) CFO receives new stock options and RSU grant - Stock Titan
Wall Street Zen Upgrades Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock Rating - National Today
Amylyx Pharmaceuticals (AMLX) Price Target Increased by 17.82% to 15.17 - MSN
Winners Losers: How Amylyx Pharmaceuticals Inc. stock performs in weak economy2025 Market Sentiment & Real-Time Volume Surge Alerts - Naître et grandir
Amylyx Pharmaceuticals, Inc. $AMLX Position Increased by Vanguard Group Inc. - MarketBeat
Amylyx Pharmaceuticals (NASDAQ:AMLX) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Q1 EPS Forecast for Amylyx Pharmaceuticals Lifted by Analyst - MarketBeat
Amylyx (AMLX) Q4 2025 Earnings Call Transcript - AOL.com
H.C. Wainwright raises Amylyx stock price target to $34 on trial confidence - Investing.com India
H.C. Wainwright raises Amylyx stock price target to $34 on trial confidence By Investing.com - Investing.com South Africa
Amylyx Pharmaceuticals Inc (AMLX) Q4 2025 Earnings Call Highlights: Strategic Advances and ... By GuruFocus - Investing.com Canada
Amylyx Leadership Triggers Buzz With Major Insider Stock Moves - TipRanks
Amylyx (AMLX) -7.8%: Earnings Show $0 Revenue, Shelf Filing Adds Dilution Fear - Trefis
Amylyx: LUCIDITY Trial Sets Stage For Q3 Inflection Point (NASDAQ:AMLX) - Seeking Alpha
Tax-withholding sale by Amylyx Pharmaceuticals (AMLX) Chief Legal Officer - Stock Titan
Amylyx (AMLX) Co-CEO sells shares to cover RSU tax withholding - Stock Titan
Amylyx Pharmaceuticals (AMLX) CEO share sale covers tax obligations - Stock Titan
Amylyx (AMLX) CFO reports automatic tax-related sale of 7,909 shares - Stock Titan
Amylyx Pharmaceuticals (NASDAQ:AMLX) Price Target Raised to $34.00 - MarketBeat
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q4 2025 Earnings Call Transcript - Insider Monkey
The Bull Case For Amylyx Pharmaceuticals (AMLX) Could Change Following Narrower Losses And New Shelf Filings - simplywall.st
A Look At Amylyx Pharmaceuticals (AMLX) Valuation After Reduced Losses And Late Stage Pipeline Progress - Yahoo Finance
Amylyx Pharmaceuticals Inc Stock (AMLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
1.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):